Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Next Previous
Trial Profile

A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Ferric carboxymaltose (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms GeparOcto

    • Most Recent Events

    • 17 Nov 2021 Results assessing survival data, time-to-event secondary end-points of the GeparOcto trial, published in the European Journal of Cancer.
    • 21 Sep 2020 Results assessing invasive disease-free survival and overall survival, presented at the 45th European Society for Medical Oncology Congress.
    • 04 Jun 2019 Results (n=914) assessing pathologic complete response (pCR) rates according to germline mutation status in patients from this study, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top